[seopress_breadcrumbs]
Partnership

Meet with our partners from around the world

ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, USA), to develop and commercialize drugs and related technologies used in Padeliporfin VTP.

 

ImPact Biotech participates in research into localized Upper Tract Urothelial Carcinoma (UTUC), Bladder cancer, Lung cancer, Esophageal cancer, and Pancreatic cancer in collaboration with the Weizmann Institute of Science (Israel) and Memorial Sloan-Kettering Cancer Center (USA).

Weizmann Institute of Science

Padeliporfin VTP’s innovative approach was developed by Prof. Avigdor Scherz and Prof. Yoram Salomon from the Weizmann Institute of Science (WIS).

WIS is a world leader in research and treatment innovation. The collaboration with ImPact Biotech led to the formation of ImPact’s research center in Israel that enables the production and rapid targeting of new compounds prior to an in-depth pre-clinical assessment.

The partnership between WIS and ImPact Biotech has resulted in numerous projects and represents a new concept in which ImPact Biotech, in its capacity as an industrial and commercial partner, has access to academia-based innovations at an early stage of research.
This approach enables the early targeting of candidate compounds for different therapy indications. As soon as a candidate compound appears to meet industrial requirements, the WIS team initiates preliminary pre-clinical studies.

Additional compounds are under investigation for use in other tumor types as well as other therapeutic areas.

Weizmann Institute of Science
Rehovot, Israel

The Weizmann Institute of Science (WIS) is at the forefront of research and treatment innovation. The collaboration with ImPact Biotech, led to the formation of ImPact’s research center that enables the production and rapid targeting of new compounds prior to an in-depth pre-clinical assessment.

LEARN MORE
Memorial Sloan Kettering Cancer Center
New York, USA

The collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), a global leader in cancer research and treatment, initially involved conducting clinical trials but has evolved into an active research and development program focusing on the early development phases of several localized tumors. The active research and development program widely benefits from the collaboration between researchers at the Weizmann Institute and the main MSKCC research teams specialized in various cancers.

We are interested in exploring collaboration opportunities that can accelerate our development program, broaden the therapeutic application of Padeliporfin VTP therapy, and support the commercialization of our technology platform.

Are you interested in collaborating with ImPact Biotech?
CONTACT US